. contributed equally to this work.
Introduction
Prostate cancer is the most prevalent cancer and the second most common tumour-related cause of death in men in Western societies [1] , with~1.1 million new diagnoses and~3 00 000 cancer-related deaths worldwide in 2012 [2] . Postmortem studies have shown that at least some small cancer foci are present in >40% of men aged >50 years [3] . It is likely that these prostate cancers represent the higher end of the scale of malignancy because most led to increased serum PSA levels and were large enough to become detectable in prostate biopsies. The selection of the optimum therapy is a challenge, especially in patients with low-risk disease and with a life expectancy of >15 years. For such patients, management options include the entire spectrum, from active surveillance through radiation therapy to radical prostatectomy. Currently, the only established pre-treatment prognostic measures that support individual treatment decisions include Gleason grade, tumour extent on biopsy, preoperative PSA level and clinical stage.
Rapidly increasing evidence suggests that MRI of the prostate might add clinically relevant pre-treatment information. Most importantly, direct or indirect MRI guidance allows areas that are suspicious for malignancy to be targeted specifically. A multitude of studies have suggested that MRI assistance leads to higher detection rates [4] [5] [6] . Also data from several centres suggest that MRI-targeted biopsy is particularly capable of detecting high grade prostate cancer with a Gleason grade of ≥4 at high sensitivity, while low grade prostate cancer (Gleason ≤3) is less visible [6] [7] [8] . The use of MRI in the biopsy process might, therefore, enable clinicians to specifically target the 'worst' areas of a prostate cancer and thus prevent under-grading in biopsies. The success of a diagnostic tumour biopsy may also be driven by the amount of cancer tissue that becomes available for analysis. Large tissue quantities not only facilitate histological assessment but also enable more extensive molecular analyses. Many studies have recently shown that molecular features, alone or in combination, may provide clinically relevant information on prostate cancer aggressiveness [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] . We have developed a transgluteal MRI-guided biopsy approach that yields particularly large tissue quantities for analysis. In the present study, we report results from a consecutive series of 301 patients analysed using our MRI-guided biopsy and compare the findings with 659 patients analysed using TRUS-guided biopsy during the same single year period. For 250 of our patients, data from subsequent radical prostatectomy specimens were also available.
Materials and Methods

Patients
The prostate biopsies of a consecutive series of 960 patients were examined at the Institute of Pathology of the University Medical Centre Hamburg-Eppendorf between 1 May 2013 and 31 May 2014, including 659 patients who underwent TRUS-guided prostate biopsy at the Martini Clinic of the University Medical Centre Hamburg-Eppendorf and 301 patients who underwent MRI-guided prostate biopsy at the ALTA Clinic in G€ utersloh. Among these patients, 574 were diagnosed with prostate cancer and 250 patients subsequently underwent prostatectomy at the Martini Clinic. These prostatectomy specimen results were available for comparison in the present study. Radical prostatectomy specimens were processed according to a standardized protocol including complete embedding of the entire prostate [20] . All patients with previous biopsy-confirmed diagnosis of prostate cancer were excluded. Patients with prior negative biopsies and/or a diagnosis of prostatic intraepithelial neoplasia or atypia were included in the analysis. If patients had more than one biopsy during the study period, the most recent biopsy was taken. The investigators were not blinded to the indication for referral, patient age or PSA level. All data were acquired retrospectively. The use of anonymised patient data was approved by local laws/HmbKHG ( §12,2). All work was carried out in compliance with the Helsinki Declaration.
MRI-guided Biopsies
Analysis using MRI was indicated by abnormalities in DRE, PSA level, PSA velocity and, in some cases, with prior negative biopsies. Patient age, clinical symptoms, clinical characteristics and a positive family history were also included in the evaluation. CT (Sensation Cardiac 64; Siemens, Erlangen, Germany) of the pelvic region was performed first to ensure the absence of ossification or other mechanical obstacles before multiparametric MRI (1.5 Tesla MRI unit (Magnetom â Avanto; Siemens) with two non-endorectal coils (Body Matrix A Tim Coil; Siemens), each with six channels, was used to determine tumour location before biopsy. During this first MRI examination the patient lay in the supine position to reduce possible movement, and the local coils were placed in the area of the abdomen and pelvis surrounding the whole girth (Fig. 1A) . Possible extracapsular extension of the tumour, seminal vesicle invasion and neurovascular bundle involvement was noted. Radiologists with several years of expertise in reading prostate MRI interpreted the MRI images. Based on the number of positive imaging sequences and individual risk factors, a lesion was considered to be suspicious for cancer and a possible target. The Prostate Imaging Reporting and Data System (PI-RADS) scoring system was not used. For the subsequent transgluteal MRIguided biopsy of suspicious lesions the patient lay in the prone position and the coils were placed in the abdominal area to the lateral pelvic region (Fig. 1B) . MRI was used to determine the optimum biopsy needle insertion angle. The biopsy device includes an MRI-compatible biopsy gun and a coaxial system using 14-gauge needles of 16 or 20 cm in length, depending on the localization of the tumour (HistoCore â ; BIP GmbH, T€ urkenfeld, Germany). The inner needle diameter was 1.75 mm and the outer needle diameter 2.1 mm. A cleansing enema (microklist â ; Johnson & Johnson GmbH, Neuss, Germany) and diazepam (Diazepamratiopharm â ; Ratiopharm GmbH, Ulm, Germany) were given before the biopsy session. To prepare for transgluteal puncture through the foramen ischiadicum minus, skin was incised and local anaesthesia (Xylonest â 1%; AstraZeneca GmbH, Wedel,
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Germany) was applied. The 14-gauge needle was then punctured towards the prelocalized tumour-suspicious focus in the prostate (Fig. 1C) . After completion of the puncture, the needle location was checked using MRI and the location of the needle was corrected according to the result of this control MRI if needed. This procedure was repeated until the needle position was optimal for biopsy taking. After biopsy, a final MRI image was taken to control for bleeding. The mean biopsy cylinder length was 13.4 AE 3.0 mm (median 13.3 mm, range 5.7-27.6 mm).
TRUS-guided Biopsies
The series of 659 TRUS biopsies were taken transrectally using a biopsy gun with 16 This sketch of a section along the transverse plane shows schematically the transgluteal punction of the prostate. The prostate (1) and its peripheral zone (1a) and transitional zone (1b), the hip joints (2), the colon (3), the glutel muscles (4), the outer fat layer (5), parts of the local coils (6) and exemplary two biopsie needles (7) 
Results
TRUS-guided Biopsies
Prostate cancer was detected in 57.2% of 659 TRUS-guided biopsies. Patient characteristics are given in Table 1 . The Gleason grades found in these biopsies are described in Fig. 2 for the highest and the summary grades. In both analyses, the majority of patients had a Gleason grade of 3 + 3 = 6 (36.1%/ 36.1%) or 3 + 4 = 7 (28.4%/34.5%) in their biopsies, and 35.5%/29.5% had a Gleason grade of 4 + 3 = 7 or higher. Across all patients, a median of 8 (range 4-11, mean 8.3 AE 0.8) locations of the prostate were punctured, usually including apex, middle, basis, medial basis for both sides of the prostate and up to four extra locations for suspicious findings in TRUS or DRE. In total 10 528 biopsies were taken, a mean of 16.0 
MRI-guided Biopsies
Each patient had up to four, but at least one suspicious lesion (median 2, mean 2.0 AE 0.7) punctured. In total, 590 lesions (73 patients with one lesion, 174 patients with two lesions, 47 with three lesions and seven patients with four lesions) were punctured and 296 lesions (50.2%) were positive for prostate cancer. In general, six cores (range 3-12, mean 5.9 AE 1.2 cores) were taken from each suspicious focus and 12 cores per patient (range 5-23, mean 11.0 AE 3.2 cores). Across all patients, 3313 cores were taken and 1182 (35.7%) were positive for prostate cancer. The 197 patients with confirmed diagnosis of prostate cancer had 385 punctured and 296 positive suspicious lesions (76.9%). For these patients, 2124 cores were taken, of which 1182 were positive (55.6%). In the 296 cancer-positive lesions, 1652 cores were taken, of which 1182 were positive (71.5%). The median time lapse between MRI and biopsy was 1 day (range 0-144, mean 7.4 AE 16.6 days). The median time lapse between analysing the prostate biopsy and the prostatectomy at the Institute of Pathology was 43 days (range 9-273, mean 49.2 AE 32.6 days). Prostate cancer was detected in 65.4% of 301 patients who underwent MRI-guided biopsy at the ALTA Clinic in G€ utersloh. Patient characteristics are shown in Table 1 . This proportion of 65.4% in MRI-guided biopsies was significantly higher than the 57.2% in non-MRI-guided biopsies (P = 0.016). In these MRI-guided biopsies, 1-4 (mean 2.0 AE 0.7) loci had been targeted per patient. For the purpose of the present study, only the focus with the worst Gleason grade was considered because this one was considered most representative of the patient's disease. If there were two or more lesions with an identical Gleason grade (20 patients), the worst focus was defined according to the maximum length of tumour tissue in biopsy.
A comparison with TRUS-guided biopsies showed significantly higher Gleason grades for MRI-guided biopsies, irrespective of whether the Gleason grade was determined according 'the most and the worst' ( Fig. 2A ; P < 0.001) or as a summary grade including tertiary patterns ( Fig. 2B ; P < 0.001). Among the 104 patients undergoing MRI-guided biopsy without detectable cancers there were 23 cases with possible alternative causes for a lesion visible by MRI [22] . These causes included an unusually high density of normal glands (adenosis, seven cases), a large area with a particular lack of glands (fibrous nodules, three cases), calcification (one case) or dense inflammation (granulomatous, sclerosing, purulent or non-specific, 12 cases). There were 81 patients without biopsy findings that were suggestive of an 'MRI focus', although 39 of them had at least one focus with slight or moderate inflammation and 40 had at least one focus with a high grade prostatic intraepithelial neoplasia. It is noteworthy, that 12 of our patients had, as the worst finding in their biopsies, a small Gleason 3 + 3 = 6 cancer that was located centrally in only 1-3 cores and did not exceed 3 mm in maximum tumour length (five patients had a Gleason grade 3 + 3 = 6 cancer that did not exceed 1 mm). As these tumour quantities did not come close to the diameter of the corresponding 'MRI focus', we assume, that these cancers represent incidental small cancer foci that arose in a region that became visible in the MRI for other reasons.
Cancer Tissue Available for Analysis
The amount of cancer tissue available for analysis was the most striking difference between MRI-guided and TRUSguided biopsies (Fig. 3) . This held true for tumour length (37.0 AE 29.5 vs 23.0 AE 31.4 mm; P < 0.001), but was even more striking for cancer surface area (64.8 AE 51.6 vs 23.0 AE 31.4 mm 2 ; P < 0.001) and cancer volume (89.0 AE 70.9 vs 18.0 AE 24.7 mm 3 , P < 0.001) because of the marked difference in needle diameter (2.1 vs 1.25 mm). These differences in cancer tissue availability were highest in low grade cancers and partly reversed in high grade cancers (Fig. 3) . Also there was a marked difference in the proportion of cancer tissue relative to the amount of available tissue in the biopsies. Overall, in patients with prostate cancer, the proportion of tumour tissue for the TRUS biopsies was 11.9 AE 15.7% and for the MRI biopsies it was 28.7 AE 24.0% (P < 0.001), and 38.3 AE 27.2% (P < 0.001) if only the worst focus in MRI was taken. These differences were greatest in low grade cancers with Gleason grade 3 + 3 = 6 (2.6 AE 5.6% for TRUS and 8.4 AE 9.9% for MRI, P < 0.001, and 14.9 AE 17.1%, P < 0.001, if only the worst focus in MRI was taken).
Biopsy vs Prostatectomy Results
The findings from 250 prostatectomy specimens obtained from patients from our biopsy cohort are shown in Table 2 . A comparison of prostatectomies performed after MRI-guided biopsy with those performed after non-MRI-guided biopsy showed a significantly higher proportion of Gleason grade 3 + 3 = 6 cancers (P = 0.021) in non-MRI-guided biopsies. The comparison of biopsy findings with the Gleason grades observed in prostatectomy specimens showed, contrary to our expectations, no obvious difference in the concordance of findings between patients with MRI-guided and non-MRIguided biopsies (Fig. 4) . It is notable, however, that the only three pT2 cancers with a Gleason grade ≥4 + 4 = 8 (two of them with a diameter of ≤1.6 cm) were detected by MRIguided biopsies. One of them was a Gleason grade 4 + 5 = 9 cancer that was identified by MRI and hit in six out of six MRI targeted biopsies with a maximum tumour length of 11.2 mm in biopsy (Fig. 5) . There was, however, one highrisk cancer with a Gleason grade of 3 + 4 = 7 (Gleason 4: 38%) and a tertiary Gleason 5 (2%) pattern that was underestimated in our MRI-guided biopsy, where the only detectable tumour was Gleason grade 3 + 3 = 6. In this cancer, the poorly differentiated areas showed an unusual growth pattern expanding between large normal glands (Fig. 6) would result in near-normal or normal tissue texture, making such a cancer undetectable by current MRI technology. As shown before, cancers with sparse architecture that are intermixed with normal tissue or glands with dilated lumina can be missed during imaging. This is mainly found in cancers with predominant Gleason pattern 3, as in our example [23] . Details of two additional cancers that were underestimated by MRI are given in Table 3 , together with one cancer that was significantly downgraded after analysis of the prostatectomy sample.
Discussion
The rate of positive biopsies was 65.4% in the present series of 301 consecutive MRI-guided biopsies. Earlier studies have reported rates of between 38 and 59% cancer-positive cases in series of 37-265 patients [24] [25] [26] [27] [28] . The lower cancer detection rates in these studies could reflect differences in targeting accuracy, sampling density, and definitions for declaring a lesion as a target on MRI, especially in study populations that include only patients with a previous negative biopsy. Pokorny et al. [8] reported a detection rate of 69.7% for MRI-guided biopsies in 142 biopsy-naive men. The rate observed in the present study is also in the range of those reported in studies using cognitive fusion [29] [30] [31] [32] and MRIultrasonography fusion [32] [33] [34] [35] [36] , with rates of 37-76% cancerpositive cases in series of 85-890 MRI positive patients. It is noteworthy that the rate found in the present study is still one of the highest compared with other studies that included targeted biopsies only. We are confident that the MRI-visible lesion was hit by our biopsies in most, if not all, patients. This is because our biopsy procedure includes a rigorous control mechanism with continuous monitoring of the needle location during biopsy-taking. Accordingly, the present data show that findings other than cancer can lead to distinct foci visible with MRI. Such alteration may include areas of an unusually high density of normal glands (adenosis), large areas with a particular lack of glands (fibrous nodules) or dense inflammation (granulomatous or non-specific), all of which were found in the present patient cohort.
The Gleason grades of our MRI-guided biopsies were higher than those seen in non-MRI-guided biopsies during the same time period. This was expected based on recent studies that have shown improved detection rates and higher Gleason grades of prostate cancer when MRI information is used [7, 8, 32, [37] [38] [39] . Our MRI equipment includes non-endorectal coils, which we consider essential for the quality of our images. In our hands, non-endorectal coils produce fewer MRI artefacts than typical 1.5 Tesla endorectal coils, particularly in highly sensitive sequences (echo planar imaging diffusion sequence). For example, non-endorectal coils avoid compression of the prostate, inhibition of blood flow, or troublesome air in the intestine that could result in poor image quality. Our extensive sampling of six cores (range 3-12, average 5.9 AE 1.2) from each 'MRI lesion' apparently also led to the detection of some incidental carcinomas. Twelve patients had small Gleason grade 3 + 3 = 6 cancers that were located centrally in only 1-3 cores and did not exceed 3 mm in length. As these tumour quantities did not come close to the diameter of the corresponding 'MRI focus', we assume, that these cancers represent incidental small cancer foci that arose in a region that became visible in the MRI for other reasons; however, none of these 'MRI foci' had a possible explanation in histopathology, such as high density of normal glands, a lack of glands, or dense inflammation. It might also be possible that our equipment enabled us to detect a proportion of low grade cancers that would become less clearly visible in standard MRI conditions. Based on the significant proportion of low grade cancers found in the present cohort, it can be concluded that not every cancer identified by MRI needs treatment; however, criteria for active surveillance are ill-defined in case of MRIguided biopsies. It is obvious that the random biopsy criteria typically used for selecting patients for active surveillance, such as <30% of cancer-containing cores, a maximum tumour length of 5 mm or maximally one core with Gleason grade 3 + 4 = 7, are not 1:1 applicable to MRI-guided biopsies. We strongly believe that MRI-guided biopsies will eventually prove to be markedly better suited for prediction of prostate cancer aggressiveness than random prostate biopsies. This is not only caused by the selective biopsy of the 'potentially worst area of the prostate', but also by the large amount of cancer tissue that becomes available.
The amount of analysable tumour mass is often small in traditional random prostate cancer biopsies. By definition, this especially applies to biopsies suggesting low to intermediate risk. In the present series of 659 TRUS-guided biopsies, the mean interpretable tumour mass was 5.1 AE biopsy cylinders from the visible tumour mass, but also by the diameter of our needles measuring 2.1 mm in outer diameter. The nearly threefold higher tumour surface area (more than fourfold in Gleason grade 3 + 3 = 6 carcinomas), in combination with the certainty that all samples are derived from one tumour focus, enables a better histological assessment of such a focus, resembling the analysis of more representative tissue samples such as transurethral resection specimen or even prostatectomies. We therefore believe that in case of MRI-guided biopsies with a high tumour yield, it is appropriate to apply similar rules for the Gleason grading as for transurethral resections and prostatectomy samples, and to define a tertiary Gleason grade. The definition of clinically relevant prostate cancer in targeted biopsies is still a matter of debate [40, 41] . Different criteria are used to define clinical relevance. The application of systematic biopsy criteria, such as the Epstein criteria [42] , on targeted biopsy has major flaws [43] . Several studies define Gleason grade ≥3 + 4 = 7 tumours as clinically significant disease. In our daily routine, we consider a prostate cancer to be low risk if the proportion of Gleason 4 disease does not exceed 10% of the tumour mass. The present data suggest that patients with such biopsy findings have a similarly low risk of having Gleason grade ≥4 + 3 = 7 prostate cancer to those patients with a Gleason 3 + 3 = 6 cancer biopsy [44] .
Comparison of the Gleason grades obtained by MRI-guided biopsy with findings in subsequent prostatectomies from 80 patients showed good but not perfect concordance. The vast majority of patients with low-risk findings from their MRIguided biopsies also had low-risk findings in their prostatectomy specimens; however, there were also patients where the MRIguided biopsy led to an underestimate of the cancer's aggressiveness. This shows that the current MRI technology still cannot detect all high-risk prostate cancers. For example, one out of eight patients (12.5%) with Gleason grade 3 + 3 = 6 disease was found to have high-risk cancer after prostatectomy as a result of a tertiary Gleason 5 pattern involving 2% of the entire tumour mass. This cancer, which also had 38% of a Gleason 4 pattern, was particularly unusual because it grew diffusely between large normal-appearing prostate glands, explaining why this cancer was undetectable by MRI.
Several of our patients appeared to benefit from the MRIguided approach. In particular, there were three patients in whom prostate cancers with a Gleason ≥4 + 4 = 8 (two of these measuring ≤1.6 cm) were visualized and successfully hit multiple times in MRI-guided biopsy. Although the present study comprised 250 patients for whom biopsy findings could be compared with prostatectomy results, this number was still too low for sound statistical analyses. From the present data we cannot prove that the MRI-guided approach is superior for detecting clinically significant cancer. Nevertheless, there was no statistically significant difference in the concordance rate between biopsy results and prostatectomy data between MRI-and TRUS-guided biopsies. This would suggest that most clinically significant cancers can also be reliably diagnosed by TRUS biopsies. There are only a few studies comparing MRI-guided biopsies with prostatectomy findings. One earlier study, analysing 142 men undergoing MRI-guided biopsy and 223 men with TRUS biopsies, suggested a better prediction of the Gleason grades in the 75 prostatectomy specimens by MRI-guided biopsies, with 80% correctly assessed tumours in contrast to 71% in TRUS-guided biopsies [8] . Another study, by Zhang et al. [45] , in 40 patients who underwent radical prostatectomy, found that TRUS-guided MRI-directed biopsies had a higher concordance rate with the final pathology than TRUS-guided biopsies for the overall highest Gleason grade (89.6 vs 72.9%) and for the Gleason scores (77.1 vs 52.1%). Le et al. [46] obtained the best predictive accuracy (81%) in their combination of targeted biopsy and systematic mapping biopsy in 54 consecutive men undergoing radical prostatectomy after fusion biopsy, and found no significant difference between targeted and systematic biopsy regarding overall performance when using only the highest Gleason pattern. Hambrock et al. [47] reported better overall concordance with prostatectomy for MRI-guided biopsies (concordance rate of 88% in 34 patients) using only the highest Gleason grades in prostatectomy specimens, in contrast to TRUS-guided biopsies (concordance rate of 55% in 64 patients). Their TRUS-guided biopsy resulted in undergrading of tumours identified with highest Gleason grade 4 to 5 in prostatectomy specimens in 46% of patients, while for MRI-guided biopsy undergrading in only 5% of patients was reported.
While in the present study MRI-guided biopsies were not substantially better in diagnosing high-risk cancers than TRUS-guided biopsies, it appears that a major advantage of MRI-guided biopsies is the lower chance of detecting clinically insignificant cancers. Given the high rate of insignificant cancer detected at autopsy in men aged >50 years, it is conceivable that limitation of the diagnostic biopsy to one suspicious region of the prostate can substantially limit the risk of detecting insignificant cancer that results in unnecessary prostatectomies in anxious patients. A significant difference was indeed observed between the Gleason grades of prostatectomy specimens of the two groups. The significantly lower rate of Gleason 3 + 3 = 6 carcinomas in prostatectomy specimens after MRI-guided biopsy suggests that MRI-guided biopsies can reduce the risk of unnecessary prostatectomies in case of insignificant prostate cancer.
One of the first studies showing the principle of the transgluteal approach with MRI guidance was published in 2004, providing proof of the feasibility and safety of the procedure using comparatively simple equipment [48] . Since then, various improvements and adaptations have been accomplished. These include use of a high-field 1.5 Tesla MRI unit for better resolution [49, 50] , patient treatment in a lateral and/or prone position [48] [49] [50] , and addition of a body coil in combination with the endorectal coil for improved image quality [50] . In the present study, we combined these former improvements and completely waived the endorectal coil. Given that only few studies have been performed to date [48] [49] [50] , it becomes obvious that experience with MRI-guided transgluteal biopsy techniques remains limited and that standardized procedures are not yet available. However, we strongly feel that the transgluteal approach has several benefits compared with transrectal approaches. For example, the transgluteal approach might also improve targeting areas such as the anterior and apical region, which are frequently under-sampled by transrectal devices. Furthermore, the coaxial system allows multiple samples to be taken from a single entry site. In addition, the risk of injury to the bladder, bowl loops and external iliac vessels is possibly minimized because of accurate positioning of the needle stabilized by the gluteal muscles [51] with repeated correction of the needle position. Antibiotic prophylaxis, a standard procedure in TRUS approaches, which can, however, contribute to antibiotics resistance [52] , is not necessary in the transgluteal 374 © 2017 The Authors BJU International © 2017 BJU International approach. A transgluteal approach results in a low incidence of infections and major complications [48, 50] . Transgluteal access without transrectal devices and/or endorectal coils also enabled guided biopsies in cases of contraindication to endorectal devices as bowel diseases or anorectal surgery [53] . Finally the absence of general anaesthesia and endorectal devices should lead to an improvement in patient comfort. Using the prone position for transgluteal biopsies might minimize motion by the patient compared with the lateral position in other transgluteal MRI approaches [50, 54] .
The present study has several limitations. First, the MRIguided cohort was selected because they had a lesion, while there was no such pre-selection in the TRUS cohort, which may contribute to the significantly higher proportion of Gleason 3 + 3 = 6 cancers in the non-MRI-guided biopsies. The ideal scenario would be a matched cohort comparison of MRI-guided and TRUS-guided patient biopsies. Second, variable numbers of biopsies in the TRUS cohort might have affected the likelihood of finding cancer. Third, it remains possible that some significant tumours may be missed by targeted and especially by systematic biopsies.
In summary, based on our data and on data from the literature, we believe that MRI-guided biopsy is becoming an increasingly relevant procedure in the management of patients with elevated PSA levels. MRI-guided and TRUS-guided biopsies are at least equally well suited for detecting clinically relevant cancers biopsies but MRI-guided biopsies reduce the risk of finding clinically irrelevant carcinomas. Moreover, patients considering active surveillance may benefit from the high quantities of cancer tissue becoming available for analysis. This is helpful not only for histological assessment. Given the advances in molecular evaluation of prostate cancer, the higher amount of tissue will greatly facilitate any molecular analyses such as nextgeneration sequencing of these biopsies. There is a rapidly increasing amount of data suggesting that such analyses will improve our ability in the near future to better predict cancer aggressiveness than by clinical and pathological features alone.
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